Core Insights - Regentis Biomaterials Ltd. has published long-term follow-up results from its Phase II clinical trial of GelrinC in the peer-reviewed journal Cartilage, marking a significant advancement in cartilage repair technology [1] - The study utilized the MOCART quantitative standard to measure cartilage regeneration, establishing GelrinC as a leader in long-term durable cartilage repair [1] - Two years post-treatment, the repaired cartilage demonstrated morphology very close to that of normal healthy cartilage, indicating the long-term durability and competitive superiority of GelrinC in the cartilage repair market [1] Company Developments - GelrinC is already approved in Europe and is currently undergoing a pivotal Phase III study with the U.S. FDA [1] - The data presented reinforces Regentis's position in the regenerative medicine sector, focusing on innovative tissue repair solutions [1]
Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation